Eli Lilly and Company (LLY) Income Statement

The sequential acceleration from 37.6% to 47.7% YoY growth over four quarters indicates that the GLP-1 franchise is not only maintaining but gaining momentum. This is likely driven by volume increases as manufacturing capacity expands, though pricing and payer mix also contribute. The durability of this growth depends on continued supply expansion and competitive dynamics, but the current trajectory suggests a multi-year growth runway.

The 500 basis point expansion in gross margin over eight quarters underscores the high-value nature of Lilly's biologic portfolio, particularly the incretin class. This margin profile is superior to peers like Novo Nordisk (81.0%) and AstraZeneca (81.9%), suggesting a structural cost advantage or superior pricing. However, investors should monitor the impact of potential U.S. drug pricing negotiations and competition from compounded versions, which could pressure gross margins over time.

While operating margin expanded from 31.2% in 2024Q1 to a peak of 47.6% in 2025Q3, the recent decline to 39.1% in 2026Q2 indicates that SG&A and R&D spending are growing faster than gross profit. This may reflect increased investment in launch activities and clinical trials. The underlying operating leverage remains positive, but the recent margin contraction warrants monitoring to see if it is a temporary blip or a trend.

The increase in R&D spending is consistent with Lilly's strategy to expand its pipeline beyond GLP-1s, including oral candidates and neuroscience. SG&A growth is driven by the global launch of obesity drugs, which requires significant promotional spend. While these costs are rising, they are growing slower than revenue, indicating that the company is achieving operating leverage. However, if revenue growth decelerates, these fixed costs could pressure margins.